Evidence map›Paper›PMID 38620775›Full record

ArticleClinical immunology communications2021

COVID-19 in a patient with Good's syndrome and in 13 patients with common variable immunodeficiency.

Hannes Lindahl, C I Edvard Smith, Peter Bergman

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical immunology communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Elevated CD21Journal of clinical immunology · 2022
    Trial
  2. Article
  3. Review
  4. Article
  5. [Patient with Good's syndrome and COVID-19. Report of a clinical case].Revista medica del Instituto Mexicano del Seguro Social · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Hannes LindahlDepartment of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.
C I Edvard SmithImmunodeficiency Unit, Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Peter BergmanImmunodeficiency Unit, Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Karolinska University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody deficiencies constitute the majority of primary immunodeficiencies in adults. These patients have a well-established increased risk of bacterial infections but there is a lack of knowledge regarding the relative risks upon contracting COVID-19. In this monocentric study the disease course of COVID-19 in 1 patient with Good's syndrome and in 13 patients with common variable immunodeficiency (CVID) is described. The severity of disease ranged from very mild to severe. Several patients required hospitalization and immunomodulatory treatment but all survived. Although viral infections are not a typical feature of humoral immunodeficiencies we recommend that vigilance is increased in the management of patients with Good's syndrome and CVID during the COVID-19 pandemic.

Indexed as

Case reportCommon variable immunodeficiencyCOVID-19Good's syndromeHumoral immunityPrimary Immunodeficiency

Identifiers

PMID38620775
PMCPMC8497938
OpenAlexW3205527275

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.